Recently, Transparency Market Research (TMR) published a new market report, “Human Microbiome Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026” and predicted that the global human microbiome diagnostic market will worth about $ 1,900 Million by the middle of 2020s.

What is microbiome and its role

Microbiome presents the genetic component of the whole scale of microorganisms, such as bacteria, fungi, protozoa, and viruses. Those microorganisms either live inside or on human bodies. They have two sides as any coin has. The beneficial bacteria present in the microbiome assist food digestion, immune system regulation, and protection against other disease-causing bacteria. Such functions have been explored by start-ups and companies in the microbiome-based therapeutics market. They wish to find drugs trying to treat diseases that are correlated to imbalance in the microbiome. In this report, the human microbiome market has been analyzed by studying it as two individual markets, namely the microbiome-based diagnostics and therapeutics market.

Increase application of Metagenomics and Next-generation Sequencing

Advances in metagenomics and next-generation sequencing have made microbiome-based testing easier and cheaper, paving the way to carry out rapid analysis of the genomic content of microorganisms from human sample. This has bolstered the development process for microbiome-based diagnostics. Gastrointestinal and metabolic disorders are likely to capture the leading share of the diagnostics market in 2018 owing to rise in interest of companies toward developing an easy analysis platform for gut health-based disorders, such as irritable bowel syndrome and Crohn’s disease. Although cancer is likely to capture a minor share of the market in 2018, much lower than gut health and metabolic disorders, it is a niche operating area for the company involved in developing a diagnostic test for detecting cancer. For instance, Metabiomics is developing molecular diagnostics for detecting markers of colorectal cancer. Existing tests for colorectal cancer rely on invasive colonoscopies; and thus, the non-invasive test developed by Metabiomics (which uses a stool sample to evaluate patient’s gut microbiome) will be a unique opportunity for the company to excel in a market having huge unmet needs.

Source: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_...

Trends in women’s health detection

When people talked about the launch of novel diagnostics and therapeutics, women’s health has been an ignored part over the past years. However, awareness regarding health and hygiene is rising among women and so is the need for products catering to their needs. For instance, in October 2016, Becton, Dickinson and Company received U.S. Food and Drug Administration (FDA) market authorization for a first-of-its-kind molecular test to detect the common causes for vaginitis. The test uses a microbiome-based algorithm for bacterial vaginosis detection. Such tests are anticipated to fuel the growth of the women’s health segment in microbiome diagnostics. In terms of technology, both metagenomic sequencing and 16s rRNA sequencing are projected to capture an equal share of the diagnostics market owing to a host of benefits associated with these techniques. The suitability of metagenomic sequencing to characterize organisms other than just bacteria is likely to make it a preferred technique for those aiming at developing tests which profile a comprehensive range of diseases.

What pushes the development of new market

Presently, there is no approved microbiome-based therapy for treatment of diseases. Overall, the anticipated launch of new drugs for gut health indications (presently in phase I/II/III) in this market during the forecast period is likely to boost the growth of the segment, and thus, contribute to the overall growth of the global therapeutics market. In the microbiome-therapeutics market, start-ups with novel candidates have begun to raise expectations on the promise of this kind of therapy. Seres Therapeutics was a prominent player to emerge as a strong contender in the market, however, phase II setback for SER-109 in 2016 made drug developers cautious with their own studies. However, Seres quickly found out that its SER-109 phase 2 study failure was caused due to misdiagnosis of certain patients and suboptimal dosing in others. Seres had started a new, redesigned clinical trial for SER-109. Thus, the zeal of scientists and clinical experts toward finding a pertinent solution to diseases with unmet medical needs using the novel approach of repopulating the affected area with the beneficial microbiota is expected to propel the market in the future.

Significant Incremental Opportunity in North America

In terms of revenue, North America is likely to continue to dominate the global human microbiome market during the forecast period, owing to early adoption of technologies and large number of ongoing clinical trials. The region is projected to be a highly attractive market for gastrointestinal disorder, with a significant attractiveness index. According to the CDC, it has been estimated that in the U.S., Clostridium difficile infection (CDI) is one of the top three critical and urgent antibiotic-resistant bacterial threats. Around 820,000 patients in the U.S. experience a first occurrence of CDI every year; and recurrent CDI has been estimated to affect up to 110,000 patients every year.

Unfortunately, the only treatment available for CDI presently is antibiotics, which can only worsen the problem on subsequent infections. The success of Fecal Microbiota Transplantation in clinical trials is a starting point for many companies to venture into the microbiome-based therapeutics domain. Moreover, start-ups in the microbiome market have been spin-offs of prestigious universities in the U.S. This is likely to boost the market for microbiome-based therapies in North America.

Genomic sequencing solutions

Next-generation sequencing (NGS) technologies have demonstrated the capacity to sequence DNA at unprecedented speed, and has made a striking impact on genomic research. By sequencing the whole human genome, people are able to unravel the complexity of the human genome in terms of genetic variations. As an effective alternative strategy to whole genome sequencing, whole exome sequencing (WES) is a powerful and cost-effective way to get deep insight into the disease-associated variations. For research only on the regions of interest, target sequencing provides ultra-high resolution of the selected regions, which lays significant foundations for variations detection.

Genomics Solutions Include

Whole Genome Sequencing. Comprehensive genome re-sequencing solutions for samples from human and other species, ensure high coverage and great accuracy.

Microbial Whole Genome Sequencing. Individual bacterial and fungal whole genome shotgun sequencing, sequenced with both Illumina HiSeq and PacBio SMRT technologies.

Whole Exome Sequencing. Powerful and cost-effective alternative to Whole Genome Sequencing. Enrichment of exome with panels provided by Agilent, Illumina or Nimblegen.

Targeted Region Sequencing. Comprehensive services from strategy design and custom data analysis. More samples can be sequenced within a sequencing run.

Author's Bio: 

Equipped with advanced NGS platforms, state-of-the-art technologies, and coupled with specialized scientists, CD Genomics delivers a broad array of genomic solutions to meet your diverse research goals and budgets.